We investigated overall and subgroup-specific female breast cancer rates to provide a comprehensive analysis of trends over several decades. Incidence, mortality, and survival, as well as age-, stage-, and birth cohort-specific incidence were analysed using nationwide cancer registry data on 163,694...
of several HER2-targeted agents, including monoclonal antibodies, tyrosine-kinase inhibitors and antibody–drug conjugates, has increased cure rates in patients with early stage HER2-positive (HER2+) breast cancer and substantially improved survival for patients with advanced-stage HER2+ breast cancer. ...
Background Trastuzumab reduces the risk of relase in women with HER2+ early stage breast cancer. Yet, little information exists on the timing of trastuzumab initiation and its association with relase and survival outcomes in these atients. The study aimed to investigate the imact of delaying ...
A comparison of survival rates between American and Japanese patients with breast cancer. Surg Gynecol Obstet. 1963;117:196-200.PubMedGoogle Scholar 22. Sakamoto G, Sugano H. Pathology of breast cancer: present and prospect in Japan. Breast Cancer Res Treat. 1991;18(suppl 1):S81-S83....
Each individual drug class has improved patient outcomes and, importantly, the combinatorial and sequential use of different HER2-targeted therapies has increased cure rates in the early stage disease setting and substantially prolonged survival for patients with advanced-stage disease. In this Review, ...
Forty-three of 107 (40 %) HER2-positive patients were classified as Luminal-type by BluePrint and may have lower response rates to targeted therapy. Molecular subtyping identified 90 of 435 (21 %) patients as Luminal A-type (BluePrint Luminal-type/MammaPrint Low Risk) with excellent survival...
1,2 Investigators observed an objective response rate (ORR) of 22% in the margetuximab arm versus 16% with trastuzumab. Drug maker MacroGenics plans to release overall survival (OS) data in the second half of 2021. The company said that margetuximab is the first HER2-targeted therapy to ...
Katz, MD, MPH JAMA Key Points Question Is germline variant status of BRCA1/2 and non-BRCA1/2 breast cancer predisposition genes associated with higher response rates in patients enrolled in the GeparOcto trial? Findings In this secondary analysis of 914 patients included in a randomized ...
At the 2024 ASCO Annual Meeting, Cascone reported on the clinical outcomes from CheckMate 77T for patients with baseline stage III N2 and non-N2 NSCLC.1 Stage IIIA to B resectable NSCLC is generally linked with poor survival outcomes, with 5-year overall survival (OS) rates ranging from...
18. A tumour was classified as luminal B-like if (1) it had positive oestrogen receptors, HER2 negative and Ki-67 high or negative progesterone receptor or (2) positive oestrogen receptors and positive HER2. A cancer was considered HER2 positive (non-luminal) if it was oestrogen and ...